Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients.
We examined peripheral blood progenitor cell (PBPC) collections and CD(34+)-selected fractions cultured in PIXY321, a fusion protein comprising analog interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) domains, for the presence of contaminating tumor cells from 14 patients with advanced-stage breast cancer. Five of the 14 (36%) pre-culture PBPC specimens contained immunocyto-chemically (ICC)-detectable tumor cells using two different cocktails of monoclonal antibodies (mAbs). After 10 days in culture with PIXY321, the CD(34+)-selected fractions showed a median 23.6-fold expansion of hematopoietic cells. No ICC-positive tumor cells were detected in any post-culture specimens. We conclude that in vitro expansion of CD(34+)-selected PBPCs with PIXY321 can expand hematopoietic cell populations apparently without risk of expanding contaminating breast cancer cell populations.
BIS Laboratories, Reseda, CA, USA.
A A
AA
Ross
M
M
Loudovaris
B
B
Hazelton
C H
CH
Weaver
L
L
Schwartzberg
J G
JG
Bender
D000911:Antibodies, Monoclonal; D018952:Antigens, CD34 / Q000032:analysis; D001943:Breast Neoplasms / Q000473:pathology*; D002469:Cell Separation; D002470:Cell Survival; D003470:Culture Media; D005260:Female; D005434:Flow Cytometry; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007377:Interleukin-3 / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D018952:Antigens, CD34; D003470:Culture Media; D007377:Interleukin-3; D011993:Recombinant Fusion Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor